Skip to main content
Beximco Pharmaceuticals Ltd. logo

Beximco Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · BXP ISIN · US0885792061 LEI · 213800IMBBD6TIOQGB56 IL Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2026-03-05 Regulatory Filings
Country BD Bangladesh
Listing IL BXP

About Beximco Pharmaceuticals Ltd.

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd. is a manufacturer of generic drugs and active pharmaceutical ingredients (APIs). The company produces a broad portfolio of over 500 products across various therapeutic categories, with a focus on providing access to affordable medicines. It has established a strong market differentiation through a range of high-tech, specialized products, including metered-dose and dry powder inhalers. Serving numerous emerging and developed markets globally, its manufacturing facilities are accredited by major international regulatory authorities, including those of the USA, European Union, Australia, and Canada.

Recent filings

Filing Released Lang Actions
Update on Writ Petitions
Regulatory Filings
2026-03-05 English
Order re Extension to Publish Financial Results
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement regarding a legal dispute between Beximco Pharmaceuticals PLC and the Bangladesh Securities and Exchange Commission (BSEC) concerning the publication of financial results and the appointment of independent directors. It details a Writ Petition filed in the High Court. Since this document describes ongoing legal proceedings and regulatory challenges rather than being a financial report, a dividend notice, or a management change announcement, it falls under the 'Legal Proceedings Report' category.
2026-01-28 English
Delay in Results & Temporary Suspension
Regulatory Filings Classification · 1% confidence The document is an official announcement from Beximco Pharmaceuticals PLC regarding a delay in the publication of its annual results and a subsequent temporary suspension of trading in its GDRs on the AIM exchange. It is distributed via the Regulatory News Service (RNS). While it discusses the annual report, it is not the report itself, but rather a regulatory disclosure regarding corporate status and compliance with AIM rules. Therefore, it falls under the RNS category.
2025-12-19 English
Request of Extension to Publish Q1 Results
Report Publication Announcement Classification · 1% confidence The document is an announcement from Beximco Pharmaceuticals PLC regarding a request for an extension to publish its first-quarter financial results due to ongoing legal and regulatory issues involving the Board of Directors. It is distributed via RNS (Regulatory News Service) and is clearly an announcement about a reporting delay rather than the financial report itself. Given it does not fit into specific categories like M&A or dividend announcements, and serves as a general regulatory update regarding filing timelines, it is best classified as a Regulatory Filing (RNS).
2025-11-13 English
Change of Name to Beximco Pharmaceuticals PLC.
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals Ltd regarding a corporate name change. It does not fit into specific categories like financial reports, dividends, or director dealings. Since it is a general regulatory announcement regarding corporate structure/identity that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-11-04 English
Request of Extension to Publish Financial Results
Report Publication Announcement Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals Ltd regarding a request for an extension to publish its annual financial results. It does not contain the financial results themselves, but rather informs the market about a delay due to ongoing legal and regulatory proceedings involving the Board of Directors. As it is a regulatory announcement that does not fit into specific categories like 'Annual Report' or 'Earnings Release', and is not a report publication announcement (since it announces a delay, not the availability of a report), it is best classified as a general regulatory filing.
2025-10-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.